Forbes 30 Under 30 Names Curebase CEO Tom Lemberg to it's 2022 List
December 1, 2021
The 30 Under 30 list honors leaders who are making impactful positive change across the world.
Since 2017, Curebase has enrolled more than 10,000 patients in over 40 decentralized clinical studies. Tom led the team through a global pandemic, helping multiple sponsors obtain Emergency Use Authorization from the FDA through decentralized trials. His resilience, optimism, and passion for advancing healthcare are at the core of Curebase's mission to enable any patient, anywhere to participate in clinical trials
At Curebase, our mission is to bring quality medical innovations to patients faster and improve human wellbeing through more efficient clinical studies. We are proving that clinical research can be radically accelerated if we empower physicians everywhere to enroll patients in the communities where they live. By applying cutting edge clinical software and remote study management techniques to the problem, we are reinventing clinical trials and research from the ground up.